Trials / Completed
CompletedNCT03006887
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma \[excluding uveal melanoma\]).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenvatinib | lenvatinib capsules |
| DRUG | pembrolizumab | pembrolizumab intravenous infusion |
Timeline
- Start date
- 2017-01-12
- Primary completion
- 2020-04-15
- Completion
- 2020-04-15
- First posted
- 2016-12-30
- Last updated
- 2021-05-20
- Results posted
- 2021-05-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03006887. Inclusion in this directory is not an endorsement.